The Australian medical landscape is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in scientific trials for treating obesity. This https://free-bookmarking.com/story21840404/retatrutide-australia-a-emerging-prospect-for-obesity-treatment